Table 1.

MMP plasma and CD8 immune activation levels in RRMS patients and healthy donors.

	HD	RRMS
		Natalizumab infusion number
		0	3	6	12	15	18	24
MMP-9	0.07 [0.01–0.14]	0.10 [0.06–0.16]	0.08 [0.06–0.13]	0.09 [0.08–0.14]	0.08 [0.05–0.15]	0.11 [0.08–0.16]	0.12 [0.06–0.22]	0.15 [0.09–0.23]
MMP-2	0.06 [0.04–0.07]	0.08 [0.06–0.09]	0.07 [0.06–0.09]	0.07 [0.07–0.09]	0.07 [0.06–0.09]	0.08 [0.07–0.09]	0.082 [0.08–0.10]	0.07 [0.06–0.09]
MMP-9/MMP-2	1.14 [0.73–1.77]	1.61 [0.80–2.28]	1.44 [0.62–2.18]	1.35 [1.07–1.93]	1.32 [0.66–2.16]	1.38 [1.05–2.88]	1.46 [0.62–2.68]	1.90 [1.24–2.92]
CD8 HLA-DR+CD38+	0.95 [0.64–1.9]	1.59 [0.94–2.24]	4.17 [2.60–5.71]	2.93 [1.49–4.34]	1.97 [1.32–3.54]	3.21 [2.20–4.96]	2.25 [0.81–3.84]	2.95 [1.64–5.44]

MMP levels are expressed as OD × mm². CD8 immune activation is expressed as percentage of CD8.

HD: heathy donors. RRMS: relapsing-remitting multiple sclerosis. Data are represented as median values and [interquartile range].